Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Namrata Sen

DARK SECRETS: Sarepta therapeutics surges over 40 in tuesday pre market what s going on | Vintage Vibes

Konskie,,Poland,-,February,24,,2024:,Sarepta,Therapeutics,Company,Logo

Stock of Sarepta Therapeutics Inc. (NASDAQ:SRPT) surged 41.05% in Tuesday pre-market following the U.S. Food and Drug Administration’s (FDA) recommendation to lift the voluntary hold on Elevidys, Sarepta’s gene therapy for Duchenne Muscular Dystrophy.

What Happened: The FDA advised the removal of the voluntary hold on Elevidys, which had been implemented after the demise of an 8-year-old patient in Brazil. The FDA determined that the death was unlikely to be related to treatment with Elevidys, the only approved gene therapy for Duchenne.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.